What we're reading, December 28, 2015: patients fight for Medicaid coverage of expensive hepatitis C treatment, Express Scripts develops programs to protect insurer's from pricey new drugs, and Republicans divided over Medicaid expansion.
Individuals are pushing back at states that are restricting access to curative treatment for hepatitis C, citing cost reasons. Patients in Indiana—one of 34 states where Medicaid refuses to pay for the $95,000 Harvoni unless there’s proof of liver damage—have filed a class action lawsuit to gain access to the pill and ensure Medicaid covers for it, according to a report by the National Public Radio.
By developing optional programs that include newer expensive drugs, Express Scripts is protecting its clients and their budgets from going topsy-turvy, reports AIS Health. With the Hepatitis Cure Value and Cholesterol Care Value Programs in place, the benefit manager is planning to unveil the Oncology Care Value Program and the Inflation Protection Program come January 2016. With an initial focus on prostate cancer, lung cancer, and renal cell carcinoma, patients covered by participating plans will receive “clinically appropriate and cost-effective medication for a specific indication,” according to Express Scripts senior vice president, Clinical, Research & New Solutions, and Chief Innovation Officer Glen Stettin, MD.
Republicans are divided over the Affordable Care Act (ACA), especially when it comes to Medicaid expansion in the states. According to The New York Times, Republican state governors who want to expand the reach of the ACA within their state are facing grief from Republican members in Congress who do not believe the law holds credibility. While Republican governors in Arizona, Arkansas, Indiana, Iowa, Michigan, Nevada, New Jersey, New Mexico, and Ohio, have expanded Medicaid, governors of South Dakota, Tennessee, and Utah are working towards it.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More